Abstract
Glucocorticoids are the mainstay of treatment of idiopathic retroperitoneal fibrosis (IRF). However, relapses are frequent upon tapering of the glucocorticoid dose. A variety of traditional immunosuppressants have been proposed as steroid-sparing agents, but some patients fail to adequately respond to combined glucocorticoid and immunosuppressive therapy. We report a patient with IRF refractory to combined glucocorticoid and methotrexate therapy treated with the anti-TNF-α monoclonal antibody infliximab. Infliximab was administered at 5 mglkglbodyweight at week 0,2, 6 and 8-weekly thereafter for 3 consecutive years. Drug efficacy and safety were assessed clinically and by laboratory tests at treatment onset and subsequently before each infusion. In addition, 18F-Fluorodeoxyglucose (FDG) positron emission computerised tomography (PET/CT) and abdominal CT scans were used to monitor disease activity and response to treatment. Infliximab therapy resulted in a satisfactory clinical and laboratory response paralleled by an improvement in imaging findings. No serious adverse events were noted. Infliximab may be an effective and safe treatment for refractory IRF. A controlled study is required to confirm our findings.
| Original language | English |
|---|---|
| Pages (from-to) | 776-778 |
| Number of pages | 3 |
| Journal | Clinical and Experimental Rheumatology |
| Volume | 30 |
| Issue number | 5 |
| Publication status | Published - 2012 |
Fingerprint
Keywords
- Idiopathic retroperitoneal fibrosis
- Infliximab
ASJC Scopus subject areas
- Rheumatology
- Immunology
- Immunology and Allergy
Cite this
Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis. / Catanoso, M. G.; Spaggiari, L.; Magnani, L.; Pipitone, N.; Versari, A.; Boiardi, L.; Pazzola, G.; Pattacini, P.; Salvarani, C.
In: Clinical and Experimental Rheumatology, Vol. 30, No. 5, 2012, p. 776-778.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis
AU - Catanoso, M. G.
AU - Spaggiari, L.
AU - Magnani, L.
AU - Pipitone, N.
AU - Versari, A.
AU - Boiardi, L.
AU - Pazzola, G.
AU - Pattacini, P.
AU - Salvarani, C.
PY - 2012
Y1 - 2012
N2 - Glucocorticoids are the mainstay of treatment of idiopathic retroperitoneal fibrosis (IRF). However, relapses are frequent upon tapering of the glucocorticoid dose. A variety of traditional immunosuppressants have been proposed as steroid-sparing agents, but some patients fail to adequately respond to combined glucocorticoid and immunosuppressive therapy. We report a patient with IRF refractory to combined glucocorticoid and methotrexate therapy treated with the anti-TNF-α monoclonal antibody infliximab. Infliximab was administered at 5 mglkglbodyweight at week 0,2, 6 and 8-weekly thereafter for 3 consecutive years. Drug efficacy and safety were assessed clinically and by laboratory tests at treatment onset and subsequently before each infusion. In addition, 18F-Fluorodeoxyglucose (FDG) positron emission computerised tomography (PET/CT) and abdominal CT scans were used to monitor disease activity and response to treatment. Infliximab therapy resulted in a satisfactory clinical and laboratory response paralleled by an improvement in imaging findings. No serious adverse events were noted. Infliximab may be an effective and safe treatment for refractory IRF. A controlled study is required to confirm our findings.
AB - Glucocorticoids are the mainstay of treatment of idiopathic retroperitoneal fibrosis (IRF). However, relapses are frequent upon tapering of the glucocorticoid dose. A variety of traditional immunosuppressants have been proposed as steroid-sparing agents, but some patients fail to adequately respond to combined glucocorticoid and immunosuppressive therapy. We report a patient with IRF refractory to combined glucocorticoid and methotrexate therapy treated with the anti-TNF-α monoclonal antibody infliximab. Infliximab was administered at 5 mglkglbodyweight at week 0,2, 6 and 8-weekly thereafter for 3 consecutive years. Drug efficacy and safety were assessed clinically and by laboratory tests at treatment onset and subsequently before each infusion. In addition, 18F-Fluorodeoxyglucose (FDG) positron emission computerised tomography (PET/CT) and abdominal CT scans were used to monitor disease activity and response to treatment. Infliximab therapy resulted in a satisfactory clinical and laboratory response paralleled by an improvement in imaging findings. No serious adverse events were noted. Infliximab may be an effective and safe treatment for refractory IRF. A controlled study is required to confirm our findings.
KW - Idiopathic retroperitoneal fibrosis
KW - Infliximab
UR - http://www.scopus.com/inward/record.url?scp=84870261334&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84870261334&partnerID=8YFLogxK
M3 - Article
VL - 30
SP - 776
EP - 778
JO - Clinical and Experimental Rheumatology
JF - Clinical and Experimental Rheumatology
SN - 0392-856X
IS - 5
ER -